Earning Preview: Linde PLC this quarter’s revenue is expected to increase by 7.62%, and institutional views are positive

Earnings Agent
Jul 24

Abstract

Linde PLC will release second-quarter 2026 results on July 31, 2026 Pre-MKt; this preview highlights consensus expectations for revenue, margins, and adjusted EPS, alongside segment dynamics and the dominant analyst stance.

Market Forecast

Consensus points to revenue of 8.99 billion US dollars for the current quarter, implying year-over-year growth of 7.62%, with EBIT of 2.71 billion US dollars, up 8.99%, and adjusted EPS of 4.48, up 11.20%; the company’s gross margin and net profit margin are expected to remain resilient, with mix and pricing tailwinds referenced in its prior update. The main businesses are projected to remain stable with packaged gases, merchant, and onsite each contributing, while packaged gases is expected to lead near-term momentum; electronics and clean hydrogen-related opportunities continue to underpin medium-term growth. The most promising segment near term is packaged gases at 3.04 billion US dollars last quarter, supported by pricing and resilient end-markets, with a constructive trajectory into the current quarter.

Last Quarter Review

Last quarter revenue was 8.78 billion US dollars, gross profit margin was 48.49%, GAAP net profit attributable to shareholders was 1.86 billion US dollars with a net profit margin of 21.15%, and adjusted EPS was 4.33, all year-over-year positives. Net profit rose 21.37% quarter on quarter, while operating discipline and portfolio mix supported margins and outperformance versus internal targets. By business, packaged gases generated 3.04 billion US dollars, merchant delivered 2.59 billion US dollars, onsite contributed 2.16 billion US dollars, and other was 1.00 billion US dollars; packaged gases provided the largest revenue base and remained the key earnings anchor.

Current Quarter Outlook

Main business trajectory and volume mix

The company’s core packaged gases, merchant, and onsite channels form a balanced portfolio entering the quarter. Pricing remains a key lever, helping offset flattish to modest volume variability across industrial end markets such as healthcare, food and beverage, and manufacturing. A steady backlog of onsite projects and strong contract structures provide visibility on utilization and cash conversion, supporting stable gross margin profile despite energy cost pass-through dynamics.

In packaged gases, ongoing price realization and low churn in specialty applications support sustained revenue per unit, while healthcare and food end-markets continue to show relatively defensive demand. In merchant, the company benefits from route density and asset optimization, which mitigate volume softness in cyclical end markets. Onsite is supported by multi-year take-or-pay agreements; incremental start-ups and reliability improvements add to both revenue and EBIT, limiting downside risk if volumes soften in discrete geographies.

Across the portfolio, foreign exchange and energy pass-through can create optical swings in top-line, but margin hold remains supported by indexing mechanisms. Working capital discipline and procurement benefits continue to offset inflation pockets in distribution and logistics. The quarter is set up for a modest year-over-year improvement in revenue, with further operating leverage in EBIT given the pricing backdrop.

Most promising growth engine

Packaged gases stands out as the most dependable near-term growth driver, aided by continued pricing power and stable volumes in healthcare, labs, and electronics specialty gases. Last quarter’s 3.04 billion US dollars of revenue provides a high base increasingly enhanced by mix upgrades into higher value applications. The business benefits from a large installed customer footprint and multi-year contract renewals, enabling UPS-like route optimization that protects margins.

As semiconductor capital spending and advanced packaging buildouts continue globally, demand for ultra-high-purity gases and specialty mixtures supports incremental growth and superior margins. Over the next quarter, the combination of price carryover, favorable mix, and sustained service reliability should allow packaged gases to outgrow the rest of the portfolio in adjusted EBIT terms. This growth can be realized without significant new capital deployment, enabling strong free cash conversion.

Onsite project startups linked to clean fuels, hydrogen, and low-carbon oxygen applications add an emerging tailwind, yet these programs contribute more visibly over multi-quarter horizons. For the current quarter, packaged gases offers a clearer and quicker path to incremental earnings contribution, with a measured volume outlook and continuing price execution.

Key stock price swing factors this quarter

Three variables are poised to influence the stock in the near term: price-cost spread, volume in cyclical end markets, and project execution cadence. Price realization relative to energy and logistics costs is central; stable or improving spread would support further EBIT expansion. Volume in metals, chemicals, and electronics can swing within the quarter—softer PMI prints could limit upside, whereas a stabilization in industrial activity would provide a helpful demand floor.

Project execution and the schedule of onsite start-ups can influence both top-line recognition and investor confidence on the multi-year capex-to-cash narrative. Any update on hydrogen pipeline investments, carbon capture tie-ins, or semiconductor gas supply contracts will likely be parsed for scale and returns. Lastly, FX translation can remain a modest headwind or tailwind depending on the dollar path; however, contractual pass-throughs limit net margin exposure.

Analyst Opinions

Market commentary over the past six months skews positive, with the majority highlighting consistent margin execution and a favorable pricing backdrop into the quarter. Analysts note the company’s capacity to beat EBIT and EPS through disciplined cost control and price carryover, and they view the packaged gases portfolio as a near-term outperformer. Well-known institutional voices emphasize resilient demand across healthcare-linked applications and visibility from long-term onsite contracts, framing a constructive setup for the print. Overall, the balance of opinion is bullish, pointing to upside risk to consensus EPS if price-cost spreads remain favorable and onsite projects ramp on schedule.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10